Medical Watch Disease & Treatment News

Multiple distinct strategies are showing early promise against Alzheimer's by targeting different disease drivers.

• 40 Hz light and sound therapy...

The FDA approved Lumvoa (veligrotug-vvze) as the first targeted TED therapy with labeling for both active and chronic disease, showing rapid proptosis...

A new lipid nanoparticle platform delivers full-length antibodies into cells, potentially treating cancer, inflammation, and neurodegenerative...

Cell therapy is moving rapidly into autoimmune disease, pediatric brain tumors, and osteoarthritis, backed by fresh regulatory momentum.

• Autoimmune...

Gedatolisib could offer new hope for ~37,000 U.S. patients yearly with HR+/HER2- breast cancer lacking PIK3CA mutations, where current PI3K inhibitors...

• Annovis Bio finished Phase 3 enrollment of 850 early Alzheimer's patients for buntanetap, with symptomatic data due Q1 2027 and disease-modifying...

Alzheimer's treatment is moving beyond amyloid clearance toward glial-targeted strategies that address neuroinflammation directly.

• Pepinemab blocks...

Two distinct therapies are advancing treatment options for devastating pediatric neurological diseases.

• T-cell therapy achieved multi-year...

• C-BRAIN consortium launched three open-source AI tools that synthesize literature, analyze unpublished "dark" data, and offer peer-review feedback...

Regulatory Milestones

• 🔥 ST002 Dual Designations: Santo Therapeutics' ST002 gene therapy received FDA Orphan Drug Designation and Rare Pediatric...

• Unified data power: BARBARA links 180 dementia databases nationwide to pre-screen and match participants efficiently.
• Recruitment accelerator:...

Santo Therapeutics' ST002 gene therapy received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA on March 10, 2026,...

• Glioblastoma therapy faces tumor antigen heterogeneity, blood-brain barrier limits, and immunosuppressive microenvironments.
• Ex vivo CAR T...

Regenerative injections and biomaterial kits reversed osteoarthritis in animal joints within 4-8 weeks, restoring healthy cartilage and bone. The...

KCL-286, already cleared in human Phase 1 trials, boosts DNA repair via BRCA1 and reduces microglial inflammation in Tg2576 Alzheimer's mice,...

• 34-circRNA signature reflects biological changes across the full A/T/N/X spectrum, from preclinical stages through MCI and Alzheimer's.
• Validated...

• Cerebral vasospasm after aneurysmal subarachnoid hemorrhage drives poor outcomes despite nimodipine and invasive interventions.
• The non-invasive...

• Rapid onset: Children and young adults with OTOF mutations gained measurable hearing within 4-6 weeks of one cochlear injection
• Wide age range:...

Germline WWOX mutations trigger severe developmental and epileptic encephalopathy, directly linking the gene to critical brain development processes and highlighting potential targets for future therapies.

• Comparable outcomes: Weekly 500 mg subcutaneous autoinjector and biweekly 10 mg/kg IV doses proved bioequivalent, with similar amyloid reduction and...